CDT Equity (NASDAQ:CDT) Announces Earnings Results

CDT Equity (NASDAQ:CDT) issued its earnings results on Wednesday. The company reported ($5.56) EPS for the quarter, FiscalAI reports.

CDT Equity Stock Performance

Shares of CDT stock opened at $0.35 on Thursday. The firm has a market capitalization of $1.71 million, a PE ratio of -0.00 and a beta of 1.49. CDT Equity has a 1 year low of $0.34 and a 1 year high of $461.54. The stock has a fifty day moving average of $0.95 and a two-hundred day moving average of $12.58.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on CDT shares. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a research report on Wednesday, June 24th. Wall Street Zen cut shares of CDT Equity to a “strong sell” rating in a report on Saturday, June 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, CDT Equity has a consensus rating of “Sell”.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.